SCHEMBL1867851

SCHEMBL1867851

CCOC(=O)C1=CC2(CCC1S(=O)(=O)Nc1ccccc1N)OCCO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 5/20 0.42
ALDH1A1 P00352 3/20 0.36
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 3/20 0.36
CDC25B P30305 2/20 0.36
KDM4E B2RXH2 2/20 0.36
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.34
MAPK1 P28482 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HPGD P15428 2/20 0.34
RECQL P46063 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
PTGER4 P35408 1/20 0.33
MRGPRX1 Q96LB2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1861053 0.90 TLR4 (0.43) TLR4ALDH1A1HSD17B10TSHRKDM4E
SCHEMBL1866081 0.90 TLR4 (0.42) TLR4ALDH1A1HSD17B10SMN1; SMN2TSHR
SCHEMBL1859103 0.89 TLR4 (0.42) TLR4ALDH1A1HSD17B10SMN1; SMN2TSHR
SCHEMBL1859769 0.89 TLR4 (0.42) TLR4ALDH1A1HSD17B10SMN1; SMN2TSHR
SCHEMBL1866325 0.89 TLR4 (0.49) TLR4HSD17B10SMN1; SMN2TSHRKDM4E
SCHEMBL1862805 0.89 TLR4 (0.50) TLR4ALDH1A1HSD17B10SMN1; SMN2TSHR
SCHEMBL1866089 0.89 KDM4E (0.42) TLR4ALDH1A1HSD17B10SMN1; SMN2TSHR
SCHEMBL1869924 0.88 TLR4 (0.41) TLR4ALDH1A1HSD17B10TSHRKDM4E
SCHEMBL1868580 0.88 MRGPRX1 (0.45) TLR4ALDH1A1HSD17B10SMN1; SMN2KMT2A
SCHEMBL1864914 0.88 TLR4 (0.43) TLR4ALDH1A1SMN1; SMN2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF TLR4 29/4885ALDH1A1 4252/4885HSD17B10 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.